The Importance of Electrocardiography in Pediatric Patients with Pulmonary Arterial Hypertension in Follow- up
Authors
Abstract:
Background: Right Ventricular (RV) hypertrophy is an adaptive response to chronic RV pressure overload in patients with pulmonary hypertension. We investigated the relationships between RV hypertrophy indicators, including electrocardiography, the percentage oxygen saturation (SaO2%), body mass index (BMI), and blood uric acid levels in patients with a biventricular structure followed up for Pulmonary Arterial Hypertension (PAH). Materials and Methods: This retrospective study included 33 patients with confirmed systemic PAH, according to the catheterization and a negative vascular reactivity test result. Patients with single-ventricle physiology and Down’s syndrome who had undergone surgery were excluded. The data of blood chemistry, hemogram, ECG, and SaO2% were collected, thus, the BMI was calculated. The patients were categorized according to SaO2 values (<90% [n=14] vs. >90% [n=19]), BMI (18.5 [n=17] kg/m2), PAH status (primary [n=13] vs. secondary [n=20]), and treatment regime (combination therapy [n=16] vs. monotherapy [n=17]), and the data were compared among the groups. Results: Patients with SaO2 values of <90% and >90% differed only in terms of blood uric acid level, which was significantly higher in the patients with SaO2<90%. The V1–V2 R-waves indicating right ventricular hypertrophy were significantly higher in patients with a BMI Conclusion: Low BMI, SaO2 <90%, elevated uric acid levels, and an elevated R-wave in V1 or V2 were associated with poor functional capacity. In particular, the D1 S-wave was significantly higher in patients who received combination therapy, with a height >9 mm indicating impaired capacity. These measured markers can be used to follow-up patients with PAH.
similar resources
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.
Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after i...
full textBosentan in Pediatric Patients with Pulmonary Arterial Hypertension
OBJECTIVE: In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH). SOURCES: 3 databases (MEDLINE, EMBASE and BIOSIS) were searched for the period January 2000 October 2007 using the key words 'pulmonary arterial hypertension',...
full textEvaluation of Pulmonary Hypertension In First Degree Relatives Of Patients With Primary Pulmonary Hypertension
Background: Pulmonary hypertension (PH) was defined for the first time in 1951 as primary pulmonary hypertension (PPH). Some studies emphasized on the role of genetics in the development of pulmonary hypertension in family members of affected patients. So, in this study we evaluated the prevalence of pulmonary hypertension in first degree family of patients with documented PPH. Methods: In thi...
full textTHE EFFECTS OF CAPTOPRIL ON PULMONARY AND SYS TEMIC ARTERIAL PRESSURES IN HIGHALTITUDE PULMONARY HYPERTENSION
The purpose of this investigation was to assess the effect of captopril on both systemic (P.a) and pulmonary arterial pressures (PPA) in patients with high-altitude pulmonary hypertension (HAPH). Seventeen patients (mean age 44±6.8 years) with HAPH and mild to moderate systemic arterial hypertension were included in the study. All patients underwent right heart catheterization with measurem...
full textMy Resources
Journal title
volume 8 issue 7
pages 11543- 11550
publication date 2020-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023